Trial · NCT05373134
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in AaPO2 gradient by at least 5mmHg or to a value less than 15mm Hg at the end of 6 months from baseline | 6 months | |
| Secondary | Change in grading of intrapulmonary shunting at the end of 3 month, from baseline as assessed by saline contrast echocardiography | 3 months | |
| Secondary | Change in grading of intrapulmonary shunting at the end of 6 month, from baseline as assessed by saline contrast echocardiography | 6 months | |
| Secondary | Change in DLCO (Diffusing Capacity of the lungs for Carbon Monoxide) at the end of 3 month from baseline | 3 month | |
| Secondary | Change in Forced expiratory volume 1 (FEV1) at the end of 3 month from baseline | 3 month | |
| Secondary | Change in FVC (Forced Vital Capacity) at the end of 3 month from baseline | 3 month | |
| Secondary | Change in FEV1/FVC ratio at the end of 3 month from baseline | 3 month | |
| Secondary | Change in 6-minute walk test at the end of 3 month from baseline | 3 month | |
| Secondary | Change in DLCO (Diffusing Capacity of the lungs for Carbon Monoxide) at the end of 6 month from baseline | 6 month | |
| Secondary | Change in Forced expiratory volume 1 (FEV1) at the end of 6 month from baseline | 6 month | |
| Secondary | Change in FVC (Forced Vital Capacity) at the end of 6 month from baseline | 6 month | |
| Secondary | Change in FEV1/FVC ratio at the end of 6 month from baseline | 6 month | |
| Secondary | Change in 6-minute walk test at the end of 6 month from baseline | 6 month | |
| Secondary | Change in seated oxygen saturation at 3 month from baseline | 3 month | |
| Secondary | Change in PaO2 at 3 month from baseline | 3 month | |
| Secondary | Change in seated oxygen saturation at 6 month from baseline | 6 month | |
| Secondary | Change in PaO2 at 6 month from baseline | 6 month | |
| Secondary | Change in inflammatory markers at the end of 3 month from baseline | 3 month | TNF alpha levels, vWF, ET-1, IL-6, S-1-P levels |
| Secondary | Change in inflammatory markers at the end of 6 month from baseline | 6 month | TNF alpha levels, vWF, ET-1, IL-6, S-1-P levels at the end of 6 month from baseline |
| Secondary | Change in inflammatory markers at the end of 3 month from baseline in a subset of patients wherever feasible | 3 month | VEGFR-3, iNOS, eNOS and IL-1 β |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05373134/registered